Genocea Biosciences (NASDAQ:GNCA) Receives New Coverage from Analysts at StockNews.com
by Doug Wharley · The Cerbat GemStockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research note published on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a 12 month low of $0.00 and a 12 month high of $0.00. The firm has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Featured Articles
- Five stocks we like better than Genocea Biosciences
- What is Forex and How Does it Work?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What is Put Option Volume?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Why is the Ex-Dividend Date Significant to Investors?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally